US Patent No: 5,580,756

Number of patents in Portfolio can not be more than 2000

B7IG fusion protein

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BRISTOL-MYERS SQUIBB COMPANYPRINCETON, NJ1913

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brady, William Bothell, WA 42 1172
Damle, Nitin K Renton, WA 31 1051
Ledbetter, Jeffrey A Seattle, WA 120 3387
Linsley, Peter S Seattle, WA 83 2323

Cited Art Landscape

Patent Info (Count) # Cites Year
 
GENENTECH, INC. (1)
* 5,336,603 CD4 adheson variants 140 1992
 
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (1)
* 4,399,216 Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials 539 1980
 
ROCHE MOLECULAR SYSTEMS, INC. (2)
* 4,683,202 Process for amplifying nucleic acid sequences 3535 1985
* 4,683,195 Process for amplifying, detecting, and/or-cloning nucleic acid sequences 3061 1986
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (6)
* 2003/0219,436 Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein 17 2002
* 2004/0054,158 GL50 molecules and uses therefor 5 2002
* 2006/0115,484 Apo-2 receptor 7 2005
* 2006/0084,147 Apo-2 receptor 11 2005
* 2006/0073,570 Apo-2 receptor 11 2005
8,435,952 Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis 4 2011
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (4)
6,682,741 .beta.2 microglobulin fusion proteins and high affinity variants 4 2001
* 2004/0091,492 Beta2 microglobulin fusion proteins and high affinity variants 0 2003
* 2009/0274,666 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE 7 2008
* 2009/0317,368 B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE 7 2009
 
EMERGENT PRODUCTIVE DEVELOPMENT SEATTLE, LLC. (1)
8,409,577 Single chain multivalent binding proteins with effector function 4 2007
 
PRESIDENT BIOSYSTEMS (1)
* 2004/0009,528 Protein chips 1 2002
 
BRISTOL-MYERS SQUIBB COMPANY (31)
* 6,887,471 Method to inhibit T cell interactions with soluble B7 13 1999
* 2002/0031,510 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith 33 2001
7,094,874 Soluble CTLA4 mutant molecules 25 2001
* 2002/0182,211 Soluble CTLA4 mutant molecules and uses thereof 9 2001
* 2002/0039,577 Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes 25 2001
* 2003/0083,246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule 6 2001
7,304,033 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 24 2002
* 2003/0022,836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 1 2002
7,915,395 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell 2 2002
7,311,910 Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions 5 2003
* 2005/0169,919 CTLA4 molecules and IL4-binding molecules and uses thereof 2 2003
7,541,164 Mammalian cell culture processes for protein production 13 2003
7,332,303 Product quality enhancement in mammalian cell culture processes for protein production 47 2003
* 2005/0084,933 Product quality enhancement in mammalian cell culture processes for protein production 5 2003
* 2005/0019,859 Mammalian ceII culture processes for protein production 9 2003
7,307,064 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 18 2004
* 2005/0123,539 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 0 2004
7,439,230 Methods of treatment using CTLA4 mutant molecules 7 2004
7,572,772 Soluble CTLA4 mutant molecules 2 2007
7,700,556 Methods of treatment using CTLA4 mutant molecules 4 2007
7,671,022 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 0 2007
7,829,534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 1 2007
7,915,222 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis 4 2009
8,227,420 Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID 3 2010
8,148,332 Method for treating a rheumatic disease using a soluble TLA4 molecule 3 2011
8,785,398 Methods of treatment using CTLA4 mutant molecules 0 2011
8,497,247 Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule 3 2012
8,722,632 Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule 0 2013
8,703,718 Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule 0 2013
9,012,408 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis 0 2013
9,296,808 Methods for treating scleroderma by administering a soluble CTLA4 molecule 0 2014
 
MAXYGEN, INC. (4)
* 7,183,376 Variant B7 co-stimulatory molecules 0 2001
* 2003/0138,881 Novel co-stimulatory molecules 4 2001
* 2005/0154,189 Novel co-stimulatory molecules 2 2004
7,612,170 Co-stimulatory polypeptides 0 2006
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (7)
7,794,710 Methods of enhancing T cell responsiveness 13 2002
* 2003/0039,653 Methods of enhancing T cell responsiveness 19 2002
* 7,432,351 B7-H1 variants 14 2003
9,062,112 B7-H1, a novel immunoregulatory molecule 0 2008
8,981,063 B7-H1 Antibodies 0 2009
8,747,833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 2 2011
8,460,927 B7-H1 antibodies and method of use 2 2011
 
Trubion Pharmaceuticals (1)
7,754,209 Binding constructs and methods for use thereof 15 2003
 
DANA-FARBER CANCER INSTITUTE, INC. (4)
* 6,071,716 DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells 15 1993
6,653,444 Polypeptides comprising a B7 extracellular domain 6 1995
* 2002/0182,727 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells 4 2002
* 2006/0233,795 Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells 0 2006
 
TRUBION PHARMACEUTICALS, INC. (6)
* 2005/0238,646 Binding domain-immunoglobulin fusion proteins 61 2005
* 2005/0202,012 Binding domain-immunogloubulin fusion proteins 23 2005
* 2005/0202,023 Binding domain-immunoglobulin fusion proteins 60 2005
* 2005/0202,534 Binding domain-immunoglobulin fusion proteins 63 2005
* 2005/0186,216 Binding domain-immunoglobulin fusion proteins 27 2005
* 2005/0175,614 Binding domain-immunoglobulin fusion proteins 60 2005
 
WYETH (3)
7,029,674 Methods for downmodulating immune cells using an antibody to PD-1 49 2002
8,088,905 Nucleic acids encoding antibodies against PD-1 2 2009
* 2010/0028,330 METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES 2 2009
 
Immunex Corporation (6)
* 7,244,822 BTL-II proteins 0 2003
7,709,618 BTL-II nucleic acids 0 2007
* 2009/0142,801 BTL-II NUCLEIC ACIDS 0 2007
8,173,603 Methods of using BTL-II proteins 0 2010
* 2010/0330,104 METHODS OF USING BTL-II PROTEINS 0 2010
8,674,078 Methods of using BTL-II proteins 1 2012
 
United States of America (1)
* 2003/0161,827 Therapies that improve graft survival 2 2002
 
Emergent Product Development Seattle, LLC (13)
* 2003/0133,939 Binding domain-immunoglobulin fusion proteins 118 2002
7,754,208 Binding domain-immunoglobulin fusion proteins 14 2002
7,829,084 Binding constructs and methods for use thereof 12 2003
* 2005/0136,049 Binding constructs and methods for use thereof 52 2003
8,106,161 Binding domain-immunoglobulin fusion proteins 3 2005
8,333,966 CD37 immunotherapeutics and uses thereof 4 2009
* 2011/0171,208 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF 10 2009
9,101,609 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof 0 2009
8,147,835 Binding domain-immunoglobulin fusion proteins 4 2009
8,197,810 Binding domain-immunoglobulin fusion proteins 2 2010
8,188,237 Binding domain-immunoglobulin fusion proteins 2 2010
8,853,366 Binding domain-immunoglobulin fusion proteins 0 2012
9,005,612 Binding domain-immunoglobulin fusion proteins 0 2012
 
GENECRAFT, INC. (1)
* 2004/0058,445 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB 25 2002
 
CANCURE LIMITED ACN 164 438 359 (2)
9,050,352 Immunomodulating compositions and uses therefor 0 2004
* 2007/0207,161 Immunomodulating Compositions and uses Therefor 17 2004
 
ASAHI KASEI KABUSHIKI KAISHA (1)
* 6,638,741 Differentiation-suppressive polypeptide serrate-2 0 2001
 
GENENTECH, INC. (11)
* 2002/0150,993 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 6 2002
7,807,153 Apo-2 receptor agonist antibodies 0 2003
* 2004/0009,552 Apo-2 receptor 12 2003
* 2005/0069,983 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 5 2004
7,750,118 Apo-2 receptor polypeptides 0 2005
* 2006/0035,334 Apo-2 receptor 11 2005
7,749,755 Apo-2 receptor polynucleotides 0 2005
7,595,046 Treatment of cancer using anti-Apo-2 antibodies 2 2005
* 2006/0141,573 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same 5 2005
7,939,631 APO-2 receptor polypeptides 0 2010
8,092,799 Antibodies to Apo-2 receptor polypeptides 0 2010
 
BIOGEN INC. (13)
7,175,847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 6 2000
7,192,585 CD80 specific antibodies 8 2005
* 2005/0260,205 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof 0 2005
7,425,447 Host cells expressing 7C10 and 16C10 CD80-specific antibodies 2 2006
7,414,123 Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies 0 2006
* 2008/0038,254 Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 0 2006
7,417,128 7C10 and 16C10 CD80-specific antibodies 2 2006
* 2007/0128,185 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2006
7,510,712 Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies 2 2007
7,510,713 Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies 0 2007
7,501,264 Methods of producing 7C10 and 16C10 CD80-specific antibodies 0 2007
7,491,393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies 2 2007
* 2009/0012,271 IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 0 2007
 
VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (1)
* 7,446,189 Nucleic acids encoding mutant human CD80 and compositions comprising the same 2 2000
 
The United States of America as represented by the Secretary of the Navy (1)
* 6,685,941 Methods of treating autoimmune disease via CTLA-4Ig 27 1995
 
AMGEN INC. (8)
7,435,796 Antibodies which bind B7RP1 7 2000
* 8,624,010 Nucleic acids encoding B7RP1 0 2000
* 7,153,669 Nucleic acids encoding MK61 receptors 1 2001
* 7,569,387 Antibody to TNF receptor-like molecules 0 2006
* 2008/0152,651 Novel polypeptides involved in immune response 3 2007
8,470,317 B7RP-1 antagonists 0 2008
8,309,083 Polypeptides involved in immune response 0 2010
* 2011/0059,068 POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE 3 2010
 
BIOGEN IDEC INC. (1)
6,926,895 Treatment of Crohn's disease using anti-CD80 antibodies that do not inhibit the binding of CD80 antigen to CTLA-4 0 2000
 
Heska Corporation (2)
7,053,181 Canine and feline B7-2 proteins, compositions and uses thereof 0 2004
7,385,045 Canine B7-1 nucleic acid molecules 1 2005
 
Human Genome Sciences, Inc. (2)
* 6,261,801 Nucleic acids encoding tumor necrosis factor receptor 5 2 1998
7,511,017 Methods of treatment with TNFR5 0 2005
 
GENETICS INSTITUTE, LLC (6)
7,011,833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent 4 2000
7,521,532 GL50 polypeptides 7 2002
* 7,459,544 Nucleic acids encoding B7-2 fusion proteins 0 2003
* 7,601,813 Anti-GL50 antibodies 7 2005
* 2006/0099,635 Anti-GL50 antibodies 6 2005
7,976,840 Use of anti-GL50 antibodies for the downmodulation of an immune response 1 2009
* Cited By Examiner